Neurocrine Biosciences (NBIX) Inventory Average (2017 - 2026)

Neurocrine Biosciences has reported Inventory Average for 10 years, with the latest figure at $66.8 million in Q1 2026.

• For the quarter ending Q1 2026, Inventory Average rose 14.59% year-over-year to $66.8 million; the trailing twelve-month figure through Mar 2026 stood at $66.8 million (up 14.59% YoY), and the FY2025 full-year result was $63.2 million, up 32.08% from the prior year.
• Inventory Average for Q1 2026 stood at $66.8 million, down from $69.1 million in the prior quarter.
• The five-year high for Inventory Average was $69.1 million in Q4 2025, with the low at $29.2 million in Q2 2022.
• Historically, Inventory Average has averaged $44.0 million across 5 years, with a median of $37.8 million in 2024.
• Annual changes were most pronounced in 2023 — Inventory Average dropped 8.75% — and 2025, when it surged 54.3%.
• Neurocrine Biosciences' Inventory Average stood at $36.0 million in 2022, then retreated by 6.93% to $33.6 million in 2023, then jumped by 53.8% to $51.6 million in 2024, then soared by 34.01% to $69.1 million in 2025, then fell by 3.47% to $66.8 million in 2026.
• The last three Inventory Average figures came in at $66.8 million (Q1 2026), $69.1 million (Q4 2025), and $63.1 million (Q3 2025), per Business Quant data.